文献速递糖尿病

血浆神经酰胺预测2型糖尿病患者的全因死亡与病因特异性死亡

Plasma Ceramides Predict All-Cause and Cause-Specific Mortality in Individuals With Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

在新加坡纳入1903例2型糖尿病门诊患者的前瞻性研究中,检测血浆神经酰胺并计算CERT1评分。中位随访9.3年发生252例死亡,高CERT1评分(≥7)较低评分(≤2)与全因死亡风险升高相关,且CERT1对非心血管死亡的关联在调整肾脏指标后仍显著。

要点

  • CERT1评分≥7者较≤2者全因死亡风险升高,校正心血管肾脏危险因素后仍显著。
  • CERT1每增加1单位与全因死亡风险升高8%相关。
  • CERT1与心血管死亡的关联在校正肾脏指标后无统计学显著性。

核心结论

  • CERT1评分可独立于临床心血管肾脏危险因素预测死亡风险。
  • 作者认为需进一步研究以阐明神经酰胺与死亡尤其是非心血管死亡的机制联系。

研究设计与样本

  • 前瞻性研究,纳入新加坡一家区域医院和一家初级保健机构的1903例2型糖尿病门诊患者。
  • 采用质谱法检测血浆神经酰胺(d18:1/16:0、d18:1/18:0、d18:1/24:0、d18:1/24:1)并据此计算CERT1评分。
  • 主要结局为全因死亡与病因特异性死亡。

主要发现

  • 中位随访9.3年期间共识别252例死亡事件。
  • 校正包括估算肾小球滤过率和白蛋白尿在内的心血管肾脏危险因素后,CERT1评分≥7者较≤2者全因死亡风险增高1.86倍(95%CI 1.30-3.65)。
  • CERT1作为连续变量每增加1单位与全因死亡风险升高8%相关(校正HR 1.08 [1.04-1.13])。
  • 将CERT1加入RECODe死亡风险引擎显著改善10年全因死亡风险预测(AUC从0.810升至0.823,差值0.013 [0.005-0.022])。
  • CERT1与非心血管死亡的关联仍显著(校正HR 2.12 [1.32-3.42]),而与心血管死亡的关联在校正肾脏指标后无统计学显著性(校正HR 1.41 [0.78-2.56])。

局限性

  • 作者指出需进一步研究以阐明神经酰胺与死亡尤其是非心血管死亡的机制联系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The Cardiovascular Event Risk Test (CERT1) score derived from plasma ceramides has been applied clinically for cardiovascular risk assessment. OBJECTIVE: To study whether plasma ceramides predict risk of mortality in patients with type 2 diabetes. METHODS: In a prospective study that included 1903 outpatients with type 2 diabetes in a regional hospital and a primary care facility in Singapore, plasma ceramides (d18:1/16:0, d18:1/18:0, d18:1/24:0, d18:1/24:1) were measured by mass spectrometry and CERT1 score was calculated accordingly. Main outcomes were all-cause and cause-specific mortality. RESULTS: During a median of 9.3 years of follow-up, 252 death events were identified. Compared to those with low score (≤ 2), participants with a high CERT1 score (≥ 7) had 1.86-fold (95% CI, 1.30-3.65) increased risk for all-cause death after adjustment for cardiorenal risk factors, including estimated glomerular filtration rate and albuminuria. As continuous variable, 1-unit increment in CERT1 was associated with 8% increased risk for all-cause death (adjusted hazard ratio [HR] 1.08 [1.04-1.13]). Adding CERT1 onto Risk Equations for Complications Of type 2 Diabetes (RECODe) mortality risk engine significantly improved prediction of 10-year risk of all-cause death (area under the curve, 0.810 to 0.823, delta 0.013 [0.005-0.022]). The association between CERT1 and noncardiovascular death remained significant (adjusted HR 2.12 [1.32-3.42]), whereas its association with cardiovascular death became nonsignificant after adjustment for kidney measurements (adjusted HR 1.41 [0.78-2.56]). CONCLUSION: CERT1 score predicts mortality risk independent of clinical cardiorenal risk factors. Further studies are warranted to elucidate the mechanistic linkage between ceramide and mortality, especially noncardiovascular mortality.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Liu S, Tham WK, Lee J, et al. Plasma Ceramides Predict All-Cause and Cause-Specific Mortality in Individuals With Type 2 Diabetes. J Clin Endocrinol Metab. 2025. PMID: 38849301. doi:10.1210/clinem/dgae388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。